Dr. Tripathy Discusses Biomarker Use in Clinical Trials

Debu Tripathy, MD
Published: Monday, Sep 12, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, explains that clinical trials have adapted the use of biomarkers into the design of each study.

Trials are beginning to be designed not only to look at how a biomarker influences response but also its effect on overall survival and progression-free survival. Trials will be looking for biomarkers that not only predict a response but also show an improvement in survival.

Tripathy explains it is becoming uncommon to see a trial that is not containing a biomarker investigation.

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, explains that clinical trials have adapted the use of biomarkers into the design of each study.

Trials are beginning to be designed not only to look at how a biomarker influences response but also its effect on overall survival and progression-free survival. Trials will be looking for biomarkers that not only predict a response but also show an improvement in survival.

Tripathy explains it is becoming uncommon to see a trial that is not containing a biomarker investigation.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x